Vision Shopsters: Commercial Insight: Cytotoxic Therapies - Drug launches in rare indications to offset the decline in cytotoxic sales

Growth of cytotoxics will remain static over the forecast period with a CAGR of -0.1%

. Several blockbuster products are due to undergo patent expiry over the forecast period and the loss of their branded sales will negatively impact on the growth of this market. But the launch of a number of drugs in rare indications will stabilize growth in this market and offset its decline from generic entry.

Scope

*In-depth analysis of the current and future cytotoxic therapies market across the US, 5EU and Japan, plus a rest of world snapshot

*Cytotoxic therapy sales forecasts for brands and generics from 2009 to 2019

*Assessment of the leading cancer brands and drug classes to identify key success factors within this sector

*Assess the strategies of the leading companies in the cytotoxics market

Highlights

Sales of cytotoxic drugs are forecast to decline in the seven major markets from $14 billion in 2009 to $13.9 billion by 2019, at a CAGR of -0.1%. The launch of Dacogen (decitabine; Eisai/Johnson & Johnson) and Vidaza (azacitidine; Celgene) in the 5EU and Japanese markets will slow down the decline in cytotoxic sales over the forecast period.

In 2009, Taxotere (docetaxel; Sanofi-Aventis), Eloxatin (oxaliplatin; Sanofi-Aventis) and Alimta (pemetrexed; Eli Lilly) were the top three cytotoxics, with sales over $1 billion. Alimta will remain among the top three brands in 2019, along with Dacogen and Vidaza.

The keys events to impact the cytotoxics market in the forecast period involve new drug launches, approvals into new indications and patent expiries. Several products with annual sales of over $1 billion are due to undergo patent expiry over the forecast period, however, new drug launches in rarer indications will compensate for this loss of sales.

Reasons to Purchase

*Quantify the performance of each of the marketed cytotoxic therapy cancer brands in the seven major markets over the period 2009 to 2019

*Acquire a detailed account of cytotoxic therapy cancer brand dynamics and the events that drive and limit their market growth

*Benchmark the cytotoxic therapy cancer brands against their generics and rest of class and align their 7MM performance with a rest of world snapshot

To know more about this report & to buy a copy please visit :

http://www.visionshopsters.com/product/5948/Commercial-Insight-Cytotoxic-Therapies-Drug-launches-in-rare-indications-to-offset-the-decline-in-cytotoxic-sales.html

Vision Shopsters: Commercial Insight: Cytotoxic Therapies - Drug launches in rare indications to offset the decline in cytotoxic sales

By: Vision Shopsters

POST COMMENT

Pfizer Inc looses battle for German generic-drug maker Medical coding & billing: Know the ICD-9 2011 changes Get Your Freedom With Medical Alarm Systems What A Doctor Needs To Do When Accused Of Medical Malpractice Stem Cells Have The Potential To Cure A Number Of Medical Disorders Signs of a functional Glendale Heights Walk-in Medical Clinic Medical Finance Made Easy Where To Get Medical Finance Best Acid Reflux Help - Forget Those Drugs and Discover How to Cure Your Problem Permanently Where Can You Find Medical Transcription Training With A Stipend? The Ups And Downs Of Starting A Medical Practice Biomarkers At The Cutting Edge Of Medical Research How Biomarkers Are Helping To Push Forward The Boundaries Of Medical Research